Khondrion Presents Phase II KHENERGY Trial Data
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY…
Khondrion, a leading clinical-stage pharmaceutical company focusing on small molecule therapeutics for mitochondrial diseases, today announced results from its KHENERGY…
Researchers just published the first randomized controlled trial ever to show an intervention effective at lowering the risk of dementia.…